Author Archives: Lu Rahman

#Antibody response #Biologics #Drug targets #Novel therapeutics #RNA #siRNA

Sitting down with…Michael Smyth, Galapagos UK

Michael Smyth is Medical Director at Galapagos UK, responsible for launching innovative therapies in the UK to help change the course of inflammatory disease for patients. Having studied medicine at Liverpool University, one of his personal missions is lifelong learning which is reflected in his role to strive for new treatment… Read More

#Editor's Choice #News #Opinion

#Biopharma #Cell and gene therapy

Rentschler Biopharma to build new cell and gene therapy capabilities in the UK

The Cell and Gene Therapy Catapult (CGT Catapult), an independent centre for advancing the UK’s cell and gene therapy industry, and Rentschler Biopharma, a global contract development and manufacturing organisation (CDMO) for biopharmaceuticals, have announced that Rentschler Biopharma will establish its manufacturing capability in Advanced Therapy Medicinal Products (ATMPs), including… Read More

#Editor's Choice #News

#Cell and gene therapy #Immunology / Virology & Vaccines #mRNA

Evonik strengthens strategic partnership with BioNTech on COVID-19 vaccine

Evonik is investing in the short-term expansion of its specialty lipids production which are essential for mRNA-based COVID-19 vaccines. Commercial lipid quantities are to be produced at Evonik’s Hanau and Dossenheim sites in Germany as early as the second half of 2021 as part of a strategic partnership with vaccine… Read More

#Covid-19 #Editor's Choice #News

#AI / data analytics / healthtech / informatics #Drug discovery #Therapeutics

Exscientia and University of Oxford partner on AI-driven Alzheimer’s treatments

Exscientia, an AI drug discovery company, has announced its collaboration with the Alzheimer’s Research UK University of Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease (AD). AD is the most common form of dementia worldwide, with an estimated 44 million people living… Read More

#Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines

World Health Organization experts provide guidance on use of the Oxford vaccine

The World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) has produced guidelines for the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine developed by the University of Oxford with its partner AstraZeneca. The WHO has recommended that two standard doses of ChAdOx1 nCoV-19 be administered at an 8-… Read More

#Covid-19 #Editor's Choice #News

#AI / data analytics / healthtech / informatics #Drug discovery

Optibrium investment will boost computer-aided drug discovery

Optibrium, developer of software for drug discovery, has raised significant investment from Kester Capital, a private equity firm typically. The funding  should accelerate the development of the business through organic growth and acquisition. Currently, more than 150 organisations worldwide deploy Optibrium’s technology in their research programs, including five of the… Read More

#News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Recruitment begins for Phase III trial of Janssen’s COVID-19 vaccine candidate

The University of Kentucky has been selected as a testing site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III clinical research study ENSEMBLE 2, which is evaluating the safety and efficacy of a two-dose regimen of Janssen’s COVID-19 vaccine candidate. The Phase III ENSEMBLE 2 study is… Read More

#Covid-19 #News

#Biomarkers #Drug candidates #Drug development #Drug discovery #Hits #Target validation

Evotec and Related Sciences form drug discovery and development partnership

Evotec has entered into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period. Evotec and Related Sciences will jointly discover and develop a range of therapeutic approaches for clearly defined patient populations… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Research & development

Digital innovation is unlocking new pharmaceutical research horizons

Transforming R&D: Digital innovation in the pharmaceuticals and chemicals industries, a new report by MIT Technology Review Insights, explores how leading pharmaceuticals and chemicals companies are using artificial intelligence, quantum computing, and other digital technologies to transform scientific research and enhance R&D performance. The report, produced in association with PerkinElmer… Read More

#Editor's Choice #News

#Biotherapeutics #Microbiome #Oncology #Pharmaceuticals

4D pharma collaboration with Merck and Pfizer for urothelial carcinoma

4D pharma, a pharmaceutical company looking at the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, has announced a clinical trial collaboration and supply agreement with Merck and Pfizer for BAVENCIO(R) (avelumab), the immunotherapy approved as a first-line maintenance treatment for patients with… Read More

#Cancer Research #Editor's Choice #News

#Clinical trials #mRNA #Research & development

Clinical trials investigate treatment for diabetic eye disease

A new approach to treating one of the leading causes of blindness among patients with diabetes is being tested in clinical trials which begin this month. The trial involves 48 patient volunteers with diabetic macular oedema (DMO), a disease where blood vessels leak fluid into the retina. It is the… Read More

#Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines

Oxford vaccine data on protection against COVID-19 infection from South African variant

In an analysis, submitted as a pre-print prior to peer-review publication, a two-dose regimen of the ChAdOx1 nCoV-19 vaccine provides minimal protection against mild-moderate COVID-19 infection from the B.1.351 coronavirus variant first identified in South Africa. Efficacy against severe COVID-19 infection from this variant was not assessed. The analyses being… Read More

#Covid-19 #News #Trending News

#Antibodies #Drug discovery

Flow Eighteen38, a new protein sciences service

FairJourney Biologics (FJB) and IONTAS, specialists in the discovery and optimisation of antibodies, have launched of a new protein sciences division, Flow Eighteen38. The new business unit has been introduced to accelerate customer antibody research projects, by delivering reagents, purified proteins, and characterisation data on antibody panels and leads. As… Read More

#News

#Assay development & optimisation #Drug discovery #Therapeutics

PerkinElmer launches assay kits to help advance therapeutics discovery

PerkinElmer has announced the addition of new assay kits to help further GPCR (G Protein-Coupled Receptor) therapeutic discovery. The new offerings extend the company’s GPCR analysis portfolio, which includes assays, plate readers, automation technologies and software solutions combined with siRNA, shRNA, CRISPR, and cDNA/ORF libraries to help scientists more easily… Read More

#News

#CRISPR #Mouse models

CRISPR/Cas9 genetically engineered models: IP and licensing considerations

This paid-for advertorial by Taconic Biosciences appeared in DDW Volume 22, Issue 1 – Winter 2020/21 In the following article, Dr. Caroline Horizny from Taconic Biosciences discusses the intellectual property landscape of CRISPR/Cas9-generated mouse models. The growing complexity of preclinical research for drug development has yielded an increase in the… Read More

#Regulatory

#Covid-19 #Immunology / Virology & Vaccines

Oxford AstraZeneca vaccine effective against ‘Kent’ variant

A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants. The Oxford University researchers who developed the ChAdOx1-nCoV 19 vaccine have found that it… Read More

#Editor's Choice #News #Trending News